Potential roles of Centipede Scolopendra extracts as a strategy against EGFR-dependent cancers

American Journal of Translational Research

Volumn 7, Issue 1, 2015, Pages 39-52

  Ma, Weina ^a   Zhang, Dongdong ^a   Zheng, Lei ^a   Zhan, Yingzhuan ^a   Zhang, Yanmin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell growth; Centipede scolopendra; Epidermal growth factor receptor

Indexed keywords

CENTIPEDE SCOLOPENDRA EXTRACT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MESSENGER RNA; PROTEIN KINASE B; SMALL INTERFERING RNA; TISSUE EXTRACT; UNCLASSIFIED DRUG;

ADULT; ANIMAL PRODUCT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CENTIPEDE; CENTIPEDE SCOLOPENDRA; CONTROLLED STUDY; DRUG BINDING SITE; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; MAP KINASE ASSAY; MTT ASSAY; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CHILOPODA; SCOLOPENDRA;

EID: 84925356362     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. [] Moon SS, Cho N, Shin J, Seo Y, Lee CO, Choi SU. Jineol, a Cytotoxic Alkaloid from the Centipede Scolopendra subspinipes. J Nat Prod 1996; 59: 777-779. http://www.plosone.org/article/findcited/6597569.
2. Undheim EAB and King GF. On the venom system of centipedes (Chilopoda), a neglected group of venomous animals. Toxicon 2011; 57: 512-524.
3. Gomes A, Datta A, Sarangi B, Kar PK, Lahiri SC. Isolation, purification & pharmacodynamics of a toxin from the venom of the centipede Scolopendra subspinipes dehaani Brandt. Indian J Exp Biol 1983; 21: 203-207. http://www. plosone.org/article/findcited/6597569.
4. Liu ZC, Zhang R, Zhao F, Chen ZM, Liu HW, Wang YJ, Jiang P, Zhang Y, Wu Y, Ding JP, Lee WH, Zhang Y. Venomic and Transcriptomic Analysis of Centipede Scolopendra subspinipes dehaani. J Proteome Res 2012; 11: 6197-212.
5. Bhagirath T, Chingtham B, Mohen Y. Venom of a hill centipede Scolopendra viridicornis inhibits growth of human breast tumor in mice. Indian J Pharmacol 2006; 38: 291-292.
6. Zhou QM, Wang XF, Liu XJ, Zhang H, Lu YY, Huang S, Su SB. Curcumin improves MMCbased chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMCassociated side-effects. Eur J Cancer 2011; 47: 2240-2247.
7. Tamm I, Schriever F, Dorken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol 2001; 2: 33-42.
8. Li J, Li Y, Feng ZQ, Chen XG. Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo. Cancer Lett 2009; 279: 213-220.
9. Nicholson RI, Gee JM, Harper ME.EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9S15. http://www.plosone.org/article/findcited/6597569.
10. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z, Derynck R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995; 376: 337-41.
11. Wells A.EGF receptor. Int J Biochem Cell B 1999; 31: 637-643. http://www.plosone.org/article/findcited/6597569.
12. McCune BK and Earp HS. The Epidermal1 Growth Factor Receptor Tyrosine Kinase in Liver Epithelial Cells. J Biol Chem 1989; 264: 15501-7.
13. Zhan YZ, Zhang Y., Liu CC, Zhang J, Smith WW, Wang N, Chen YN, Zheng L, He LC. A novel taspine derivative, HMQ1611 inhibits breast cancer cell growth via ERα and EGFR signaling pathways. Cancer Prev Res 2012; 5: 864-873.
14. Yarden Y and Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Bio 2001; 2: 127-37.
15. Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P, Giannopoulou I. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 2008; 10: R49.
16. Boudewijn MT and Burgering PJC. Protein kinase B (c-AKT) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995; 376: 599-602.
17. He XP, Ashwani K, Debarshi R, Kaufmann S, Shridhar V. Loss of HSulf-1 Expression Enhances Tumorigenicity by Inhibiting Bim Expression in Ovarian Cancer. Int J Cancer 2014; 135: 1783-1789.
18. Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi MJ, Khosravi-Far R, Parangi S. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/ AKT pathways. Cell Death Dis 2014; 5: e1104.
19. Senthilkumar K and Kim SK. Cell Survival and Apoptosis Signaling as Therapeutic Target for Cancer: Marine Bioactive Compounds. Int J Mol Sci 2013; 14: 2334-2354.
20. Huang SM and Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17: 259-269.
21. Merlino GT, Xu YH, Ishii S, Clark AJ, Semba K, Toyoshima K, Yamamoto T, Pastan I. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 1984; 224: 417-419.
22. Hunter T and Cooper JA. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell 1981; 24: 741-752.
23. Wu B, Zheng JF, Yu ZD, Jiang ZM, Ma G. Inhibitory effects of siRNA on expression of epidermal grow th factor receptor in squamous cell carcinoma cell line A431. J Fourth Mil Med Univ 2009; 30: 1064-1067.
24. Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, GarcíaEcheverría C, Wong KK, Engelman JA. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci 2009; 106: 19503-8.
25. Maegawa M, Arao T, Yokote H, Matsumoto K, Kudo K, Tanaka K, Kaneda H, Fujita Y, Ito F, Nishio K. EGFR Mutation Up-regulates EGR1 Expression through the ERK Pathway. Anticancer Res 2009; 29: 1111-1118.
26. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474. Cancer Res 2004; 64: 9101-9104.
27. Maegawa M, Arao T, Yokote H, Matsumoto K, Kudo K, Tanaka K, Kaneda H, Fujita Y, Ito F, Nishio K. Epidermal growth factor receptor lacking C-terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 2009; 100: 552-7.
28. Zhang Y., Li X, Xu XM, Luo WJ. Construction of a high-EGFR expression cell line and its biological properties comparing with A431 cell. Afr J Biotechnol 2010; 9: 4674-4680.
29. Liu XP and Zhong DW. Study on the mechanisms of tumor inhibitory effect of centipede extraction on heterotopic grafting hepatocellular carcinoma in nude mice. Chin J General Surg 2010; 19: 164-168.
30. Zhou YL, Luo WJ, Zhang YM. Construction of recombinant FGFR1 containing full-length gene and its potential application. Plasmid 2010; 64: 60-67.
31. Wang L, Ren J, Sun M, Wang SC. A combined cell membrane chromatography and online HPLC/MS method for screening compounds from Radix Caulophylli acting on the human alpha(1A)-adrenoceptor. J Pharm Biomed Anal 2010; 51: 1032-1036.
32. Anguizola J, Joseph KS, Barnaby OS, Matsuda R, Alvarado G, Clarke W, Cerny RL, Hage DS. Development of affinity microcolumns for drugprotein binding studies in personalized medicine: interactions of sulfonylurea drugs with in vivo glycated human serum albumin. Anal Chem 2013; 85: 4453-4460.
33. Matsuda R, Anguizola J, Joseph KS, Hage DS. Analysis of drug interactions with modified proteins by high-performance affinity chromatography: binding of glibenclamide to normal and glycated human serum albumin. J Chromatogr A 2012; 1265: 114-122.
34. Rasul A, Ding C, Li X, Khan M, Yi F, Ali M, Ma T. Dracorhodin perchlorate inhibits PI3K/AKT and NF-jB activation, up-regulates the expression of p53, and enhances apoptosis. Apoptosis 2012; 17: 1104-1119.
35. Caja L, Sancho P, Bertran E, Ortiz C, Campbell JS, Fausto N, Fabregat I. The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms. Biochem Pharmacol 2011; 82: 1583-1592.
36. Wiggins CM, Band H, Cook SJ. c-Cbl is not required for ERK1/2-dependent degradation of BimEL. Cell Signal 2007; 19: 2605-2611.
37. Dehan E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN, Dustin M, Huang DC, Taunton J, Pagano M. βTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 2009; 33: 109-116.
38. Zhang Y., Zheng L, Zhang J, Dai BL, Wang N, Chen YN, He LC. Anti-tumor activity of taspine by modulating EGFR signaling pathway of Erk1/2 and AKT in vitro and in vivo. Planta Med 2011; 77: 1774-1781.
39. Rikimaru K, Tadokoro K, Yamamoto T, Enomoto S, Tsuchida N. Gene amplification and overexpression of epidernal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck 1992; 14: 8-13. http://www. plosone.org/article/findcited/6597569.
40. Sargent ER, Gomella LG, Belldegrun A, Linehan WM, Kasid A. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol 1989; 142: 1364-1368. http://www.plosone.org/article/findcited/6597569.
41. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Cri Rev Oncol Hematol 1995; 19: 183-232. http://www.plosone.org/article/findcited/6597569.
42. Ishikawa J, Maeda S, Umezu K, Sugiyama T, Kamidono S. Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma. Int J Cancer 1990; 45: 1018-1021.
43. Kim JW, Kim YT, Kim DK, Song CH, Lee JW. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol Oncol 1996; 60: 283-287.
44. Bast RC Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A. Cell growth regulation in epithelial ovarian cancer. Cancer 1993; 71: 1597-1601.
45. Egan SE and Weinberg RA. The pathway to signal achievement. Nature 1993; 365: 781-783.
46. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature 1991; 363: 8385.
47. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-6263.
48. Zhang Y., Dai BL, Zheng L, Zhan YZ, Zhang J, Smith WW, Wang XL, Chen YN, He LC. A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation. Cell Death Dis 2012; 3: e406.